The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Role of Tyrosine Kinase Inhibitors in Cancer Therapy
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal Tumors
Hirota, S., Isozaki, K., Moriyama, Y., Hashimoto, K., Nishida, T., Ishiguro, S., Kawano, K., Hanada, M., Kurata, A., Takeda, M., et al. (1998) · Science · doi:10.1126/science.279.5350.577 · Cited by 4,490
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
Cell Signaling by Receptor Tyrosine Kinases
Schlessinger, J. (2000) · Cell · doi:10.1016/s0092-8674(00)00114-8 · Cited by 3,774
Blume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J.-Y., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.038 · Cited by 2,874
Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., Niederwieser, D., Resta, D., Capdeville, R., Zoellner, U., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011573 · Cited by 2,019
Mendel, D. B., Laird, A., Xin, X., Louie, S. G., Christensen, J. G., Li, G., Schreck, R., Abrams, T. J., Ngai, T. J., Lee, L. B., et al. (2003) · PubMed · Cited by 1,961
Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
Shah, N. P., Tran, C., Lee, F. Y., Chen, P., Norris, D., & Sawyers, C. L. (2004) · Science · doi:10.1126/science.1099480 · Cited by 1,796
Dimerization of cell surface receptors in signal transduction
Heldin, C.-H. (1995) · Cell · doi:10.1016/0092-8674(95)90404-2 · Cited by 1,634
Carpenter, G., & Cohen, S. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)38983-5 · Cited by 1,622
Herbst, R. S., Prager, D., Hermann, R., Fehrenbacher, L., Johnson, B. E., Sandler, A., Kris, M. G., Tran, H. T., Klein, P., Li, X., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.840 · Cited by 1,490
The Biology of Chronic Myeloid Leukemia
Faderl, S., Talpaz, M., Estrov, Z., O'Brien, S., Kurzrock, R., & Kantarjian, H. M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907153410306 · Cited by 1,302
Buchdunger, E., Cioffi, C. L., Law, N., Stover, D., Ohno-Jones, S., Druker, B. J., & Lydon, N. B. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38879-2 · Cited by 1,274
Sawyers, C. (2004) · Nature · doi:10.1038/nature03095 · Cited by 1,165
Fong, T. A. T., Shawver, L. K., Sun, L., Tang, C., App, H., Powell, T., Kim, Y. H., Schreck, R., Wang, X., Risau, W., et al. (1999) · PubMed · Cited by 1,109
Heinrich, M. C., Griffith, D. J., Druker, B. J., Wait, C. L., Ott, K. A., & Zigler, A. J. (2000) · Blood · doi:10.1182/blood.v96.3.925 · Cited by 1,071
Strumberg, D., Richly, H., Hilger, R. A., Schleucher, N., Korfee, S., Tewes, M., Faghih, M., Brendel, E., Voliotis, D., Haase, C. G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.124 · Cited by 872
Imatinib Mesylate — A New Oral Targeted Therapy
Savage, D. G., & Antman, K. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmra013339 · Cited by 844
BindingDB (2025) · PubMed · doi:10.7270/q2dr317m · Cited by 843
Petit, A. M. V., Rak, J. W., Hung, M., Rockwell, P., Goldstein, N. I., FENDLY, B. M., & Kerbel, R. S. (1997) · Europe PMC (PubMed Central) · Cited by 836
Ranson, M., Hammond, L. A., Ferry, D., Kris, M., Tullo, A., Murray, P. I., Miller, V., Averbuch, S., Ochs, J., Morris, C., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.112 · Cited by 763
Rusnak, D. W., Lackey, K. E., Affleck, K., Wood, E. R., Alligood, K. J., Rhodes, N., Keith, B. R., Murray, D. M., Knight, W. B., Mullin, R. J., et al. (2001) · PubMed · Cited by 728
Pao, W., & Miller, V. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.799 · Cited by 631
New Drugs for Rheumatoid Arthritis
Olsen, N. J., & Stein, C. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmra032906 · Cited by 626
Moulder, S. L., Yakes, F. M., Muthuswamy, S. K., Bianco, R., Simpson, J. F., & Arteaga, C. L. (2001) · PubMed · Cited by 597
In Vitro and In Vivo: The Story of Nonoxynol 9
Hillier, S. L., Moench, T., Shattock, R., Black, R., Reichelderfer, P., & Veronese, F. (2005) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000159671.25950.74 · Cited by 572
Smart drugs: Tyrosine kinase inhibitors in cancer therapy
Shawver, L. K., Slamon, D., & Ullrich, A. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00039-9 · Cited by 522
Rini, B. I., & Small, E. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.186 · Cited by 408
Arteaga, C. L. (2001) · PubMed · Cited by 397
Imatinib as a Paradigm of Targeted Therapies
(2004) · Advances in Cancer Research · doi:10.1016/s0065-230x(04)91001-9 · Cited by 370
Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy.
Mendelsohn, J. M. (1997) · PubMed · Cited by 344
Mutant V599EB-Raf Regulates Growth and Vascular Development of Malignant Melanoma Tumors
Sharma, A., Trivedi, N. R., Zimmerman, M. A., Tuveson, D. A., Smith, C. D., & Robertson, G. P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2423 · Cited by 321
Traxler, P., Allegrini, P. R., Brandt, R., Brueggen, J., Cozens, R., Fabbro, D., Grosios, K., Lane, H. A., McSheehy, P., Mestan, J., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3681 · Cited by 320
Normanno, N., Campiglio, M., De Luca, A., Somenzi, G., Maiello, M., Ciardiello, F., Gianni, L., Salomon, D. S., & Menard, S. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf020 · Cited by 273
Regulation and targets of receptor tyrosine kinases
Pawson, T. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)80597-4 · Cited by 264
A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia
Fiedler, W., Mesters, R., Tinnefeld, H., Loges, S., Staib, P., Dührsen, U., Flasshove, M., Ottmann, O. G., Jung, W., Cavalli, F., et al. (2003) · Blood · doi:10.1182/blood-2002-10-2998 · Cited by 262
Xia, W., Liu, L.-H., Ho, P., & Spector, N. L. (2004) · Oncogene · doi:10.1038/sj.onc.1207166 · Cited by 253
Epidermal growth factor receptor signaling
Bogdan, S., & Klämbt, C. (2001) · Current Biology · doi:10.1016/s0960-9822(01)00167-1 · Cited by 226
Mendel, D. B., Schreck, R., West, D. C., Li, G., Strawn, L. M., Tanciongco, S. S., Vasile, S., Shawver, L. K., & Cherrington, J. M. (2000) · PubMed · Cited by 215
Gilliland, D. G., & Griffin, J. D. (2002) · Current Opinion in Hematology · doi:10.1097/00062752-200207000-00003 · Cited by 202
Angiogenesis inhibitors in clinical development; where are we now and where are we going?
Eskens, F. A. L. M. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601401 · Cited by 197
Targeting epidermal growth factor receptor—are we missing the mark?
Dancey, J. E., & Freidlin, B. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13810-x · Cited by 192
Tyrosine kinase inhibitors—ZD1839 (Iressa)
Arteaga, C. L., & Johnson, D. H. (2001) · Current Opinion in Oncology · doi:10.1097/00001622-200111000-00012 · Cited by 172
Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation
Thomas, S. M., & Grandis, J. R. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2003.10.003 · Cited by 171
Anderson, K. (2003) · European Journal of Haematology · doi:10.1034/j.1600-0609.2003.01067.x · Cited by 168
CI-1033, a pan-erbB tyrosine kinase inhibitor
SLICHENMYER, W. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90285-4 · Cited by 165
Stopeck, A., Sheldon, M., Vahedian, M., Cropp, G. F., Gosalia, R., & Hannah, A. L. (2002) · PubMed · Cited by 150
Herbst, R. S., Prager, D., Hermann, R., Miller, V. A., Fehrenbacher, L., Hoffman, P. C., Johnson, B. E., Sandler, A. B., MASS, R. D., & Johnson, D. H. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.90140.7011 · Cited by 146
Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders
Pardanani, A. D., & Tefferi, A. (2004) · Blood · doi:10.1182/blood-2004-01-0246 · Cited by 137
Ko, Y. J., Small, E. J., Kabbinavar, F. F., et al. (2001) · PubMed · Cited by 136
TYROSINE KINASE INHIBITORS AND THE DAWN OF MOLECULAR CANCER THERAPEUTICS
Tibes, R., Trent, J. C., & Kurzrock, R. (2004) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.100124 · Cited by 133
Shawver, L. K., Schwartz, D. P., Mann, E., et al. (1997) · PubMed · Cited by 131
Allen, L. F., Lenehan, P. F., Eiseman, I. A., Elliott, W. L., & Fry, D. J. (2002) · Seminars in Oncology · doi:10.1016/s0093-7754(02)70122-x · Cited by 127
The Role of Erlotinib (Tarceva, OSI 774) in the Treatment of Non-Small Cell Lung Cancer
Perez-Soler, R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-040017 · Cited by 125
Epidermal growth factor receptor tyrosine kinase inhibitors
Ranson, M. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601873 · Cited by 118
Kinase Inhibitors in Cancer Therapy: A Look Ahead
Sedlacek, H. H. (2000) · Drugs · doi:10.2165/00003495-200059030-00004 · Cited by 98
Erlotinib (Tarceva): An update on the clinical trial program
Herbst, R. S. (2003) · Seminars in Oncology · doi:10.1016/s0093-7754(03)70013-x · Cited by 98
Lyseng-Williamson, K. A., & Jarvis, B. (2001) · Drugs · doi:10.2165/00003495-200161120-00007 · Cited by 94
Molecular targeting of angiogenesis
Alessi, P., Ebbinghaus, C., & Neri, D. (2003) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2003.08.001 · Cited by 84
Calvo, E., Tolcher, A. W., Hammond, L. A., Patnaik, A., Bono, J. S. D., Eiseman, I. A., Olson, S. C., Lenehan, P. F., McCreery, H., LoRusso, P. M., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1187 · Cited by 81
Predictive factors for epidermal growth factor receptor inhibitors—The bull's-eye hits the arrow
Dancey, J. E. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00122-9 · Cited by 73
Bono, P., Krause, A., von Mehren, M., Heinrich, M. C., Blanke, C. D., Dimitrijević, S., Demetri, G. D., & Joensuu, H. (2004) · Blood · doi:10.1182/blood-2003-10-3443 · Cited by 62
The vascular endothelial growth factor family and its receptors
Parikh, A. A., & Ellis, L. M. (2004) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2004.06.004 · Cited by 61
Wikstrand, C. J., & Bigner, D. D. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.11.799 · Cited by 40
Vascular Endothelial Growth Factor as a Therapeutic Target in Cancer
Bergsland, E. K. (2004) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/61.suppl_5.s4 · Cited by 37
The impact of anti-angiogenic agents on cancer therapy
Marm�, D. (2003) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-003-0488-9 · Cited by 28
Cited by
Antibody–Drug Conjugates: An Emerging Concept in Cancer Therapy
Chari, R. V. J., Miller, M. L., & Widdison, W. C. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201307628 · Cited by 930
Sunitinib: From Rational Design to Clinical Efficacy
Chow, L. Q. M., & Eckhardt, S. G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.3602 · Cited by 883
Glioblastoma multiforme: Pathogenesis and treatment
Alifieris, C., & Trafalis, D. T. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.05.005 · Cited by 820
Comparing antibody and small-molecule therapies for cancer
Imai, K., & Takaoka, A. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1913 · Cited by 792
In vivo delivery of miRNAs for cancer therapy: Challenges and strategies
Chen, Y., Gao, D.-Y., & Huang, L. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.05.009 · Cited by 672
Metadata
- Authors
- Arora, A., & Scholar, E. M.
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 2005-12
- Volume
- 315
- Issue
- 3
- Pages
- 971-979
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W1974903851
- Cited by
- 1,014
- References
- 72
- FWCI
- 24.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.